DAYANG BIOTECH issued a preliminary increase, expecting the net profit attributable to the parent company for the first three quarters to be between 74 million yuan and 90 million yuan, a year-on-year increase of 44.35% to 75.56%
I'm PortAI, I can summarize articles.
DAYANG BIOTECH expects the net profit attributable to the parent company for the first three quarters of 2025 to be between 74 million yuan and 90 million yuan, a year-on-year increase of 44.35% to 75.56%. The net profit after deducting non-recurring gains and losses is expected to be between 67 million yuan and 82 million yuan, a year-on-year increase of 39.04% to 70.17%. The growth in performance is mainly driven by market demand, with sales and prices of the main products, potassium carbonate and veterinary raw materials, rising, leading to an increase in gross profit margin
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments